Acute liver injury after transcatheter arterial chemoembolization in patients with hepatitis B virus-related intermediate or advanced hepatocellular carcinoma stages

doi:10.3748/wjg.118709

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 24

This Article

(27)

(43)

(0)

(33)

(1)

(663)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jun 28, 2026; 32(24): 118709
Published online Jun 28, 2026. doi: 10.3748/wjg.118709

Table 1 Comparison of baseline data of 172 cases of hepatitis B virus-related intermediate to advanced hepatocellular carcinoma, mean ± SD/n (%)

	Non-ALI group (n = 110)	ALI group (n = 62)	Statistic value	P value
Sex			χ² = 0.572	0.449
Male	91 (82.7)	54 (87.1)
Female	19 (17.3)	8 (12.9)
Age	60.9 ± 9.85	59.3 ± 10.2	t = 1.000	0.319
Child-Pugh stage			χ² = 5.496	0.019
A	72 (65.5)	51 (82.3)
B	38 (34.5)	11 (17.7)
BCLC			χ² = 0.011	0.917
B	47 (42.7)	27 (43.5)
C	63 (57.3)	35 (56.5)
Weight (kg)	66.5 ± 10.4	67.2 ± 11.0	t = -0.439	0.661
Height (m), median (IQR)	1.70 (1.62, 1.73)	1.65 (1.64 ,1.72)	Z = -0.646	0.518
Duration of TACE (minute), median (IQR)	60.0 (49.2, 60.0)	60.0 (51.0, 60.0)	Z = -0.538	0.590
Number of TACE			χ² = 6.305	0.012
First time	73 (66.4)	29 (46.8)
Non first time	37 (33.6)	33 (53.2)
Tumor diameter (mm), median (IQR)	40.5 (20.2, 63.0)	52.0 (36.2, 75.8)	Z = -2.515	0.012
Tumor number			χ² = 0.570	0.450
Single	38 (34.5)	25 (40.3)
Multiple	72 (65.5)	37 (59.7)
PNI, median (IQR)	193 (173, 210)	211 (190, 221)	Z = -2.912	0.004
CONUT, median (IQR)	5.00 (4.00, 6.00)	5.00 (4.00, 6.00)	Z = -1.807	0.071
GNRI	101 ± 11.8	104 ± 10.2	t = -1.975	0.050
TC (mmol/L), median (IQR)	3.82 (3.29, 4.47)	3.85 (3.36, 4.77)	Z = -1.013	0.311
AFP (ng/mL), median (IQR)	75.0 (6.10, 716)	92.9 (2.97, 1956)	Z = -0.15	0.881
HBsAg (log₁₀ IU/mL), median (IQR)	3.61 (2.40, 3.78)	3.61 (2.07, 3.79)	Z = -0.204	0.838
HBeAg (log₁₀ IU/mL)			χ² = 1.168	0.280
Negative	78 (70.9)	39 (62.9)
Positive	32 (29.1)	23 (37.1)
HBV DNA (IU/mL)			χ² = 9.253	0.010
< 20	60 (54.5)	19 (30.6)
20-2000	32 (29.1)	26 (41.9)
> 2000	18 (16.4)	17 (27.4)
ALT (U/L), median (IQR)	25.0 (17.2, 40.0)	25.0 (20.2, 41.0)	Z = -0.49	0.624
AST (U/L), median (IQR)	39.0 (23.0, 64.8)	34.5 (27.0, 51.0)	Z = -0.067	0.947
GGT (U/L), median (IQR)	89.0 (45.2, 140)	87.0 (39.8, 160)	Z = -0.408	0.683
TBIL (μmol/L), median (IQR)	15.5 (11.5, 21.6)	13.2 (10.4, 24.1)	Z = -0.955	0.339
ALB (g/L), median (IQR)	37.8 (33.2, 40.7)	41.0 (36.6, 43.0)	Z = -2.829	0.005
PT (seconds), median (IQR)	12.8 (12.1, 13.9)	12.2 (11.4, 13.3)	Z = -2.253	0.024
INR, median (IQR)	1.16 (1.09, 1.27)	1.11 (1.05, 1.21)	Z = -2.061	0.039
NLR, median (IQR)	2.45 (1.59, 3.63)	2.65 (1.70, 3.61)	Z = -0.115	0.909
WBC (× 10⁹/L), median (IQR)	4.00 (2.80, 5.92)	4.60 (3.32, 5.70)	Z = -1.300	0.194
NE (× 10⁹/L), median (IQR)	2.25 (1.58, 3.44)	2.69 (1.87, 4.01)	Z = -1.403	0.161
LYM (× 10⁹/L), median (IQR)	1.00 (0.60, 1.40)	1.10 (0.80, 1.48)	Z = -1.341	0.180
PLT (× 10⁹/L), median (IQR)	97.0 (68.0, 172)	116 (76.5, 160)	Z = -0.601	0.548

Prognostic nutritional index = albumin + lymphocyte × 5. TACE: Transcatheter arterial chemoembolization; ALI: Acute liver injury; BCLC: Barcelona clinic liver cancer staging system; IQR: Interquartile range; PNI: Prognostic nutritional index; CONUT: Controlling nutritional status; GNRI: Geriatric nutritional risk index; TC: Total cholesterol; AFP: Alpha-fetoprotein; HBsAg: Hepatitis B surface antigens; HBeAg: Hepatitis B e antigens; ALT: Alanine aminotransferase; AST: Aspartate transaminase; HBV: Hepatitis B virus; GGT: Gamma-glutamyl transpeptidase; TBIL: Total bilirubin; ALB: Albumin; PT: Prothrombin time; INR: International normalized ratio; NLR: Neutrophils to lymphocytes ratio; WBC: White blood cell; NE: Neutrophil; LYM: Lymphocyte; PLT: Platelet.

Full Size Table

Citation: Jie XH, Xi DY, Zhang SS, Yan XB. Acute liver injury after transcatheter arterial chemoembolization in patients with hepatitis B virus-related intermediate or advanced hepatocellular carcinoma stages. World J Gastroenterol 2026; 32(24): 118709
URL: https://www.wjgnet.com/1007-9327/full/v32/i24/118709.htm
DOI: https://dx.doi.org/10.3748/wjg.118709

Jie XH, Xi DY, Zhang SS, Yan XB. Acute liver injury after transcatheter arterial chemoembolization in patients with hepatitis B virus-related intermediate or advanced hepatocellular carcinoma stages. World J Gastroenterol 2026; 32(24): 118709 [DOI: 10.3748/wjg.118709]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.